PONIARD PHARMACEUT COM USD0.02 (PARD)

0.10
OTC Markets
Prev Close 0.10
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.08 / 0.22
Exchange OTC Markets
Shares Outstanding 1.50B
Market Cap 6.00M
Div & Yield N.A. (N.A)

Latest News

5 Health Care Stocks With Upside

These health care stocks are scheduled to report their quarterly earnings today.

Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Stocks Under $5 With the Most Sell Ratings

Stocks Under $5 With the Most Sell Ratings

Hovnanian and Blockbuster are among stocks under $5 with the most sell ratings from analysts.

Poniard Announces Final Data From Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer

Picoplatin Shows Activity in the Treatment of Small Cell Lung Cancer

Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Poniard, Xfone: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

Poniard Pharmaceuticals Provides Strategic Update On Picoplatin Development Program

Engages Leerink Swann LLC to Explore Strategic Alternatives for the Company; Announces Workforce Restructuring

Cell Therapeutics, Zoom Technologies: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Monday's session.

Poniard Pharmaceuticals Reports Fourth Quarter And Year End 2009 Financial Results

- Conference Call Today at 8:30 a.m. Eastern Time -

Medivation: Biotech Stock Mailbag

Medivation: Biotech Stock Mailbag

Medivation's (MDVN) Alzheimer's drug, Dimebon, failed an important drug trial. Hard lessons were learned, as explained in this bonus Mailbag.

Poniard Pharmaceuticals Announces Management Changes And Reduction In Force

Ronald A. Martell Named Chief Executive Officer

Antigenics Files $100 Million Mixed Shelf: BioBuzz

Drug maker may try to raise money as approvals of its kidney cancer drug stall out.

New Gold, Poniard: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

Poniard Drug Safe, Less Effective: BioBuzz

Can Poniard attract a partner for a chemo drug that causes less nerve toxicity but may not help patients live longer?